The biology and potential therapies involving regulatory T cells in ovarian cancer

Abstract

Ovarian cancer remains a formidable challenge in oncology, demanding innovative approaches to improve patient outcomes. This abstract delves into the intricate biology of regulatory T cells (Tregs) and their emerging roles as both contributors and potential therapeutic targets in ovarian cancer. Tregs, characterized by the expression of FOXP3, exhibit immunosuppressive properties that can impede effective anti-tumor immune responses within the ovarian tumor microenvironment. Their presence has been associated with tumor immune evasion and poorer prognosis. However, recent research highlights a paradoxical aspect of Tregs, wherein they may also help maintain immune homeostasis and limit excessive inflammation. This abstract explores the dual nature of Tregs in ovarian cancer, shedding light on their intricate interactions with other immune cell populations.Furthermore, it discusses evolving therapeutic strategies aimed at harnessing or modulating Tregs to enhance the anti-tumor immune response. These approaches include Treg depletion, blockade of immunosuppressive pathways, and the development of innovative immunotherapies. Notably, immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies, are being investigated for their potential to disrupt Treg-mediated immune suppression.Understanding the biology of Tregs in ovarian cancer and their potential as therapeutic targets opens new avenues for personalized treatment strategies, with the ultimate goal of improving outcomes for patients facing this challenging malignancy.